Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 16/20 | 0.51 |
| ▸ | CTSS | P25774 | 13/20 | 0.51 |
| ▸ | CTSK | P43235 | 12/20 | 0.51 |
| ▸ | CTSB | P07858 | 10/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | CTSV | O60911 | 2/20 | 0.37 |
| ▸ | CTSF | Q9UBX1 | 2/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24312112 | 0.79 | CTSL (0.46) | CTSLCTSSCTSKCTSBKIF11 | |
| SCHEMBL22017080 | 0.77 | PDE2A (0.46) | KIF11ALDH1A1 | |
| SCHEMBL22017352 | 0.77 | PDE2A (0.46) | KIF11ALDH1A1 | |
| SCHEMBL22017349 | 0.77 | PDE2A (0.46) | KIF11ALDH1A1 | |
| SCHEMBL22016893 | 0.77 | CTSL (0.47) | CTSLCTSSCTSKCTSB | |
| SCHEMBL16105512 | 0.77 | CTSL (0.47) | CTSLCTSSCTSKCTSB | |
| SCHEMBL22016892 | 0.77 | CTSL (0.47) | CTSLCTSSCTSKCTSB | |
| SCHEMBL22017093 | 0.76 | PRCP (0.45) | — | |
| SCHEMBL22016223 | 0.76 | PRCP (0.45) | — | |
| SCHEMBL22016889 | 0.76 | PRCP (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | CTSL 2027/4885CTSS 2859/4885CTSK 2184/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | CTSL 2816/4885CTSS 3204/4885CTSK 2608/4885 |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | CTSL 933/4885CTSS 1062/4885CTSK 987/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | CTSL 933/4885CTSS 1062/4885CTSK 987/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | CTSL 2199/4885CTSS 2419/4885CTSK 2305/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | CTSL 2027/4885CTSS 2859/4885CTSK 2184/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | CTSL 933/4885CTSS 1062/4885CTSK 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.